A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (1,304 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-10-27. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: scorepainkidney diseasechronicmoderate
  Phrases that lowered it: participantoralparticipantsmaledaily
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past trials: 2414 (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 59.6% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 6.2% (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 5.5% (lowers risk) · Drug's FDA history
• Blinding: single (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 65 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 229 (raises risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 3868 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity NCT02832375 · started 2016 · scored riskier than 6% of active trials completed
• The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity NCT03072719 · started 2012 · scored riskier than 5% of active trials completed
• Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream NCT02918617 · started 2015 · scored riskier than 6% of active trials completed
• Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice NCT07215767 · started 2025 · scored riskier than 3% of active trials completed
• The Efficacy of a Toothpaste to Reduce Sensitivity NCT00763269 · started 2008 · scored riskier than 6% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.